novo-reserpine tab 0.25mg tablet
novopharm limited - reserpine - tablet - .25mg - reserpine .25mg - peripheral adrenergic inhibitors
lennon-reserpine tablets
pharmacare limited - reserpine - tablet - reserpine tablets 0.25mg
ser-ap-es- reserpine, hydralazine hydrochloride and hydrochlorothiazide tablet, coated
novartis pharmaceuticals corporation - hydralazine hydrochloride (unii: fd171b778y) (hydralazine - unii:26nak24ls8), hydrochlorothiazide (unii: 0j48lph2th) (hydrochlorothiazide - unii:0j48lph2th), reserpine (unii: 8b1qwr724a) (reserpine - unii:8b1qwr724a) - tablet, coated - 25 mg - hypertension (see boxed warning). hypersensitivity to reserpine; mental depression or history of mental depression (especially with suicidal tendencies); active peptic ulcer, ulcerative colitis; patients receiving electroconvulsive therapy. hypersensitivity to hydralazine; coronary artery disease; mitral valvular rheumatic heart disease. anuria; hypersensitivity to this or other sulfonamide-derived drugs.
reserpine powder
bluebay shandong co.,ltd - reserpine (unii: 8b1qwr724a) (reserpine - unii:8b1qwr724a) -
reserpine powder
ax pharmaceutical corp - reserpine (unii: 8b1qwr724a) (reserpine - unii:8b1qwr724a) -
ax pharmaceutical corp- reserpine powder
ax pharmaceutical corp - reserpine (unii: 8b1qwr724a) (reserpine - unii:8b1qwr724a) - reserpine 9.9 g in 10 g
reserpine
ceva animal health pty ltd - reserpine - unknown - reserpine alkaloid active 0.0 - active constituent
nv rakelin injection
ceva animal health pty ltd - reserpine - parenteral liquid/solution/suspension - reserpine alkaloid active 0.5 mg/ml - central nervous system - horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | mare | pacer | pol - tranquilliser | calming agent | sedative
renese-r- polythiazide and reserpine tablet
pfizer labs - polythiazide (unii: 36780apv5n) (polythiazide - unii:36780apv5n), reserpine (unii: 8b1qwr724a) (reserpine - unii:8b1qwr724a) - tablet - 2 mg - hypertension (see box warning). the routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (however, see precautions/pregnancy section). dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. there is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular dis
rakelin
ceva animal health (nz) limited - reserpine - reserpine 0.5 g/litre - behaviour modifier